Generic Revlimid exclusivity loss
Revlimid exclusivity ends in FY26, which will compress revenue and margins in the U.S. business.
high · management_commentaryCipla Ltd — Q4 FY25
Cipla delivered a solid Q4 FY25 with revenue of INR 6,730 crore (+9% YoY) and EBITDA margin of 22.8% (+150bps YoY), driven by strong performance across One India (+8% YoY), Nort...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Lanreotide supply normalization uncertainty
While supplies are resuming, the timeline to regain previous market share is uncertain and may take time.
medium · analyst_questionU.S. tariff and regulatory risks
Potential U.S. tariffs on pharma imports and executive orders on pricing could impact the business, though management sees limited near-term impact.
medium · analyst_questionExecution risk on peptide and respiratory pipeline
Delays in approvals or commercial launches of key pipeline assets (peptides, Advair) could affect growth trajectory.
medium · data_observation